Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jamil Dihu

Cardiovascular Disease Evanston, IL Medical Doctor

NPI 1154508570 CMS profile 7435

2650 Ridge Ave, Evanston, IL 60201

Open in the dashboard

General payments

$83,352

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jamil Dihu of Evanston, IL is reported in the CMS Open Payments database as having received $83,352 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $143 6
2024 General $478 6
2023 General $8,292 18
2022 General $8,158 17
2021 General $14,658 26
2020 General $11,204 31
2019 General $40,420 174

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamil Dihu
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jamil Dihu were reported at $143. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jamil Dihu Cardiovascular Disease median Middle half National median
2019 $40,420 $450 $127–$1,392 $163
2020 $11,204 $242 $77–$751 $114
2021 $14,658 $335 $101–$1,037 $132
2022 $8,158 $395 $121–$1,211 $149
2023 $8,292 $443 $136–$1,283 $160
2024 $478 $450 $136–$1,323 $164
2025 $143 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $66,910 113 payments
  2. Abbott Laboratories $7,644 30 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $6,402 19 payments
  4. Novartis Pharmaceuticals Corporation $377 30 payments
  5. Abiomed $319 2 payments
  6. Penumbra, Inc. $286 2 payments
  7. Pfizer Inc. $247 11 payments
  8. Janssen Pharmaceuticals, Inc $200 16 payments
  9. Amgen Inc. $183 17 payments
  10. AstraZeneca Pharmaceuticals LP $138 9 payments
  11. Other $646 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $65,250 27 payments
  2. Food and Beverage $7,957 227 payments
  3. Consulting Fee $6,563 5 payments
  4. Travel and Lodging $3,434 15 payments
  5. Education $148 4 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Structural Heart $36,128 59 payments
  2. WATCHMAN Access System $15,542 23 payments
  3. WATCHMAN Pain Management $8,443 19 payments
  4. CardioMEMS HF System $6,557 11 payments
  5. LifeVest $6,402 19 payments
  6. WATCHMAN Watchman $3,018 2 payments
  7. WATCHMAN Structural Heart $3,000 1 payment
  8. General Therapies $709 6 payments
  9. CARDIOMEMS $572 8 payments
  10. ENTRESTO $377 30 payments
  11. Other $2,831 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

469

Median for Cardiology: 2,533

Drug cost

$44,827

Median for Cardiology: $485,213

Branded share of claims

12.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 17 $22,373
Xarelto Rivaroxaban Brand 13 $18,024
Metoprolol Succinate Generic 60 $848
Spironolactone Generic 82 $736
Atorvastatin Calcium Generic 71 $584
Nifedipine Er Nifedipine Brand 11 $451
Furosemide Generic 56 $414
Enalapril Maleate Generic 17 $332
Lisinopril Generic 32 $241
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 18 $221

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$32,167

Medicare's payments for the services billed

Medicare patients

375

Average age 71

Services billed

639

189 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Heart failure 55%
Chronic kidney disease 51%
Arthritis 49%
Ischemic heart disease 43%
COPD 32%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record